|
PURA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67399427652981E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.51212375953946E-13 |
| Normal-vs-Stage2 |
4.626000E-04 |
| Normal-vs-Stage3 |
7.76811948099976E-12 |
| Normal-vs-Stage4 |
2.81363821130753E-12 |
| Stage1-vs-Stage2 |
4.328200E-01 |
| Stage1-vs-Stage3 |
1.357030E-01 |
| Stage1-vs-Stage4 |
2.024000E-02 |
| Stage2-vs-Stage3 |
1.492000E-01 |
| Stage2-vs-Stage4 |
3.941600E-02 |
| Stage3-vs-Stage4 |
3.353800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.214800E-04 |
| Normal-vs-Asian |
1.57698999999623E-05 |
| Caucasian-vs-AfricanAmerican |
1.835220E-01 |
| Caucasian-vs-Asian |
3.698200E-01 |
| AfricanAmerican-vs-Asian |
7.694000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22124532708767E-15 |
| Normal-vs-Female |
1.43499656601875E-11 |
| Male-vs-Female |
3.408300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.22117896192731E-12 |
| Normal-vs-Age(41-60Yrs) |
1.39580014213436E-10 |
| Normal-vs-Age(61-80Yrs) |
1.67954539165294E-12 |
| Normal-vs-Age(81-100Yrs) |
2.451800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.750800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.747800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.601200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.113000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.753400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.545000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.71501999999268E-05 |
| Classical-VS-Follicular |
5.078000E-01 |
| Classical-VS-Other |
4.450200E-01 |
| Classical-VS-Normal |
1.15209952689099E-10 |
| Tall-VS-Follicular |
1.100890E-03 |
| Tall-VS-Other |
2.451200E-01 |
| Tall-VS-Normal |
2.1538326677728E-14 |
| Follicular-VS-Other |
5.610600E-01 |
| Follicular-VS-Normal |
9.65590052359744E-10 |
| Other-VS-Normal |
1.080050E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.90359950025254E-10 |
| Normal-vs-N1 |
5.41019451461011E-11 |
| N0-vs-N1 |
1.987410E-01 |
|
|
